NBS Released M1~M5 IAV of Medical & Pharmaceutical Products: Medical Devices Showed Promising Prospe

  • 2016-06-22

Recently, NBS released industrial added value (IAV) of medical & pharmaceutical products and retail sales data of Chinese and western medicines from January to May. The data showed that in May 2016, industrial added value of medical & pharmaceutical products increased by 12.2% on year-on-year basis with an acceleration rate of 1.5% compared with that in April, and the accumulated year-on-year growth from January to May is 10.2%; in May 2016, the retail sales of Chinese and western medicines reached RMB 66.7 billion, with a year-on-year growth of 14.4%, and an acceleration rate of 4.5% compared with that in April, and accumulated y-o-y growth is 13.9%.

CITICS (600030, Guba) said the y-o-y growth of IAV of medical & pharmaceutical products and detail sales of Chinese and western medicines in May picked up compared with April, indicating the continued rebound trend of fundamentals of the industry, thus the extent of industry prosperity will recover gradually. Insiders predicted that the economies of scale of pharmaceutical industry will grow steadily, where main business income will rapid growth, with average annual acceleration rate of about 10%, taking a significantly increased proportion in industrial economy by 2020.

For medical device industry, at the CEIBS 12th Annual China Health Care Forum held by MIIT, Guo Xiang, deputy director of Department of Consumer Goods Industry said the goal of “the thirteen five-year plan” is to upgrade pharmaceutical industry. To achieve this, the pharmaceutical industry shall strengthen development and application of core technical components of medical devices, implement standard action plan of medical device, develop domestic medical device product, improve design and function of such products, consolidate international orientation, and expand export scale of medical equipment, etc.

For biological medicine industry, Deep Development Mode Analysis and Research Report of Development Strategy on China Biological Medicine Industrial Cluster (2016~2020) reported that China biopharmaceutical industry started late but currently encounters a critical period for transition and improvement of pharmaceutical industry. In 2014, our biological agent market reached USD 5 billion, flat with the increase of overall pharmaceutical market. It is expected that by 2020 the Chinese biological medicine market will be the second biggest biological medicine market in the world, ranking only second to the U.S.

Search